Many patients with T2DM fail to reach their LDL-C, non-HDL-C and apoB goals with statin therapy alone, in which case combination therapy with other lipid-modifying agents has been suggested [4, 5, 7, 8, 20]. This evidence concerns the gene APOB and type 2 diabetes mellitus.